HD-OPM Archive
Topics › Heart rhythm & heart failure

Q-SYMBIO: CoQ10 cut major cardiovascular events 15% vs 26% in heart failure

Louis Nervegna · Dec 24, 2025 · ♥ 36 reactions · 6 comments · original Facebook post
Heart rhythm & heart failureSupplements & vitamins
AI summary & key facts

In the randomized Q-SYMBIO trial of 420 patients with moderate-to-severe heart failure, CoQ10 100 mg three times daily reduced major adverse cardiovascular events over 2 years, though short-term endpoints did not change.

The Q-SYMBIO Randomized Trial

Testing CoQ10 as a treatment for heart failure

Link to full study:

Paper · JACC Heart Fail · 2014The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.Conclusion: Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events. (Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIomarker status [Brain-Natriuretic Peptide (BNP)], and long-term Outcome [hospitalisations/mortality]; ISRCTN94506234).jacc.org

Quoted:

“Patients with moderate to severe HF [heart failure] were randomly assigned in a 2-year prospective trial to either CoQ10 100 mg 3 times daily or placebo, in addition to standard therapy. The primary short-term endpoints at 16 weeks were changes in New York Heart Association (NYHA) functional classification, 6-min walk test, and levels of N-terminal pro–B type natriuretic peptide. The primary long-term endpoint at 2 years was composite major adverse cardiovascular events as determined by a time to first event analysis.”

“A total of 420 patients were enrolled. There were no significant changes in short-term endpoints. The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003) by intention-to-treat analysis. The following secondary endpoints were significantly lower in the CoQ10 group compared with the placebo group: cardiovascular mortality (9% vs. 16%, p = 0.026), all-cause mortality (10% vs. 18%, p = 0.018), and incidence of hospital stays for HF (p = 0.033).”

“The following secondary endpoints were significantly lower in the CoQ10 group compared with the placebo group: cardiovascular mortality (9% vs. 16%, p = 0.026), all-cause mortality (10% vs. 18%, p = 0.018), and incidence of hospital stays for HF (p = 0.033).”

“Conclusions- Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events.”

#coq10HD #heartfailureHD #qsymbioHD

Research cited

The Q-SYMBIO randomized, double-blind, placebo-controlled trial evaluated the effect of coenzyme Q10 in 420 patients with moderate to severe chronic heart failure (NYHA class III–IV) who were already receiving standard medical therapy. Participants were given 300 mg of CoQ10 per day (100 mg three times daily) or a placebo and followed for two years. The study found that cardiovascular mortality was significantly lower in the CoQ10 group, with deaths occurring in about 9% of treated patients compared with ~16% in the placebo group, corresponding to roughly a 50% relative reduction in cardiovascular death.

Beyond mortality, the CoQ10 group also experienced fewer major adverse cardiovascular events and meaningful improvements in heart failure symptoms and functional class, indicating better day-to-day clinical status. Importantly, CoQ10 was used as an add-on, not a substitute for standard heart-failure medications, suggesting it supported cardiac energy metabolism alongside conventional therapy. While the mortality reduction was notable for a supplement-based intervention, the trial size was modest, which is why the findings are considered promising but not yet definitive without larger confirmatory studies.

No photo description available.
← newer: Coffee compounds have antifibrotic and metabolic effects on older: Low vitamin C reduced fat burning during exercise, and 500 m →